006620.KQ DongKoo Bio & Pharma Co. Ltd.
- Market cap
- KRW 85.2B
- P/E
- -
- P/B
- 0.60x
- ROE
- -9.4%
- Dividend yield
- 3.81%
- Fundamental score
- 3.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 006620.KQ undervalued?
Graham numberThe Graham number of DongKoo Bio & Pharma Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DongKoo Bio & Pharma Co. Ltd. fundamental analysis
14 of 21 checks passedROE 0/2
Low return on equity (-9.4%), below 10%.
ROA 0/1
Return on assets (-4.2%) is below the industry median (3.4%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (2,421.4%) is above the 5-year average (41.9% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (2,421.4%) is above the industry median (6.6%).
Revenue Growth 1/2
Revenue grew 7.6% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (16.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.6x) is below the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (3.8%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 6 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 6.5%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
DongKoo Bio & Pharma Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral, antifungal, antihistamines, antifebrile and anti-inflammatory analgesic, respir…
Full company profileDongKoo Bio & Pharma Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DongKoo Bio & Pharma Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 87.4B | 101B | 105B | 125B | 139B | 155B | 195B | 216B | 249B | 243B | 235B |
| Gross Profit | 52.5B | 60.9B | 61.4B | 70.7B | 80.6B | 92.4B | 118B | 132B | 152B | 144B | 136B |
| Operating Income | 10.3B | 13.3B | 5.82B | 6.46B | 7.62B | 8.14B | 17.0B | 14.6B | 12.4B | 9.25B | -9.29B |
| EBITDA | - | - | - | - | - | - | 14.6B | 22.5B | 14.0B | 73.8B | -3.25B |
| Net Income | 10.9B | 10.9B | 4.57B | 15.1B | 9.14B | 9.33B | 6.61B | 11.8B | 2.04B | 50.3B | -13.3B |
| EPS | 535 | 480 | 159 | 534 | 323 | 333 | 239 | 428 | 74 | 1,859 | -492 |
| Balance Sheet | |||||||||||
| Total Assets | 65.3B | 75.6B | 104B | 133B | 144B | 155B | 172B | 191B | 244B | 336B | 319B |
| Total Liabilities | 43.3B | 37.8B | 32.2B | 47.1B | 49.7B | 54.7B | 70.0B | 80.7B | 139B | 184B | 176B |
| Shareholders' Equity | 22.0B | 37.7B | 72.1B | 85.7B | 94.7B | 100B | 102B | 110B | 105B | 152B | 142B |
| Cash & Short-term Investments | 4.92B | 11.0B | 21.7B | 32.7B | 29.5B | 32.0B | 34.8B | 21.5B | 36.2B | 21.6B | 18.4B |
| Total Debt | 19.5B | 14.5B | 12.0B | 20.4B | 23.2B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.6B | 9.51B | -791M | 10.1B | 7.49B | 17.9B | 16.8B | 3.59B | 17.3B | -4.29B | 29.7B |
| Capital Expenditure | 6.55B | 811M | 6.16B | 8.77B | 5.27B | 4.27B | 11.1B | 16.0B | 25.5B | 20.5B | 13.9B |
| Free Cash Flow | - | - | - | -2.53B | 2.03B | 12.4B | 5.74B | -12.4B | -8.12B | -24.7B | 15.8B |
| Ratios | |||||||||||
| ROE | 49.5% | 29.0% | 6.3% | 17.6% | 9.7% | 9.3% | 6.5% | 10.7% | 1.9% | 33.1% | -9.4% |
| ROA | 16.7% | 14.5% | 4.4% | 11.4% | 6.3% | 6.0% | 3.8% | 6.2% | 0.8% | 14.9% | -4.2% |
| Net Profit Margin | 12.5% | 10.8% | 4.4% | 12.1% | 6.6% | 6.0% | 3.4% | 5.5% | 0.8% | 20.7% | -5.7% |
| Debt to Equity | 0.88x | 0.38x | 0.17x | 0.24x | 0.25x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DongKoo Bio & Pharma Co. Ltd. dividends
- Dividend yield
- 3.81%
- Forward dividend
- -
- Payout ratio
- 6.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 3.25B | 120 | 6.5% |
| 2024 | KRW 3.31B | 120 | 162.7% |
| 2023 | KRW 3.04B | 110 | 25.7% |
| 2022 | KRW 2.80B | 101 | 42.4% |
| 2021 | KRW 943M | 34 | 10.1% |
| 2020 | KRW 943M | 33 | 10.3% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | KRW 943M | 41 | 8.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 959692:319897 on Mar 2, 2021.
Who owns DongKoo Bio & Pharma Co. Ltd.
- Insiders 42.27%
- Institutions 0.33%
- Public & others 57.39%
- Shares outstanding 9.60M
- Free float 15.6M
DongKoo Bio & Pharma Co. Ltd. company profile
- Company name
- DongKoo Bio & Pharma Co. Ltd.
- Ticker
- 006620.KQ
- ISIN
- KR7006620009
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 331
- Fiscal year end
- December
- Address
- M State Building, Seoul, South Korea, 05836
- Phone
- 82 2 2684 5421
- Website
- dongkoo.com
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral, antifungal, antihistamines, antifebrile and anti-inflammatory analgesic, respiratory system, digestant, antiplatelet, other analgesics and antipyretics, nootropics and neurotonics, nonsteroidal anti-inflammatory, and oral hypoglycemic medicines; and antiphlogisnc enzyme, ophthalmic, dermatology external, and decongestants and nasal preparations, as well as non-selective a, ß-blockers and H+ pump inhibitors. It also provides cosmetic products under the CELL BLOOM brand; and SmartX, a kit-type SVF separation medical device for use in cosmetic surgery/anti-aging clinics and medical/treatments. The company was founded in 1970 and is headquartered in Seoul, South Korea.
DongKoo Bio & Pharma Co. Ltd. management
1- Mr. Cho Yong-JoonPres